Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669).
Halofantrine (WR 171,669) was administered to 27 nonimmune subjects infected with the multi-drug resistant Vietnam Smith strain of Plasmodium falciparum. It was also administered to three other subjects, one infected with the Cambodian Buchanan strain of P. falciparum, and two with blood-induced infection with the Chesson strain of P. vivax. It cured infections with all three parasites. Against the highly chloroquine-resistant Smith strain, it was curative in single day treatment regimens. The drug was well tolerated and produced rapid clearance of parasitemia in every case.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology; D010616:Phenanthrenes / Q000009:adverse effects / Q000627:therapeutic use*; D010963:Plasmodium falciparum / Q000187:drug effects; D012008:Recurrence
D010616:Phenanthrenes; C023768:halofantrine